Free shipping on all orders over $ 500


Cat. No. M3835
Alirocumab Structure

REGN 727;SAR 236553

Size Price Availability Quantity
2mg USD 680  USD680 In stock
5mg USD 1040  USD1040 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Alirocumab works by inhibiting the PCSK9 protein. PCSK9 binds to the low-density lipoprotein receptor (LDLR) (which takes cholesterol out of circulation), and that binding leads to the receptor being degraded, and less LDL cholesterol being removed from circulation. Inhibiting PCSK9 prevents the receptor from being degraded, and promotes removal of LDL cholesterol from circulation. After subcutaneous administration of alirocumab, maximal suppression of free PCSK9 occurs within 4 to 8 hours and has an apparent half-life of 17 to 20 days. Inhibition is dose-dependent. The antibody is distributed through the circulation, and it is eliminated at low concentrations by binding to its target, and at higher concentrations through a proteolytic pathway.

Product Citations
Chemical Information
Molecular Weight 145981.36
Formula C6472H9996N1736O2032S42
CAS Number 1245916-14-6
Storage -80°C for long term
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Zhang Xi, et al. Circulation Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection

[2] Jun Zhang, et al. Proc (Bayl Univ Med Cent). Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia

[3] Marian McDonagh, et al. J Manag Care Spec Pharm. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

[4] Robinson JG, et al. N Engl J Med. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

[5] Moriarty PM, et al. J Clin Lipidol. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.

Related PCSK9 Products

AZD0780 (PCSK9-IN-12, EX-A6975) is a heteroaryl compound. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism.


NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies.


CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism.


CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia.


AZD-8233 is an orally active, antisense oligonucleotide (ASO) targeting PCSK9 that targets and inhibits the translation and protein synthesis of PCSK9 mRNA in hepatocytes and reduces circulating LDL-C levels. It can be used in studies related to hypercholesterolemia.

Abmole Inhibitor Catalog

Keywords: Alirocumab, REGN 727;SAR 236553 supplier, PCSK9, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.